Published in Proc Natl Acad Sci U S A on January 26, 2010
Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. BMC Genomics (2014) 1.22
Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol (2010) 1.09
Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res (2013) 0.99
Improving T cell responses to modified peptides in tumor vaccines. Immunol Res (2013) 0.90
TCR hypervariable regions expressed by T cells that respond to effective tumor vaccines. Cancer Immunol Immunother (2012) 0.89
The Goldilocks model for TCR-too much attraction might not be best for vaccine design. PLoS Biol (2010) 0.86
Basic and translational applications of engineered MHC class I proteins. Trends Immunol (2010) 0.84
Augmenting antitumor T-cell responses to mimotope vaccination by boosting with native tumor antigens. Cancer Res (2012) 0.84
Improving antigenic peptide vaccines for cancer immunotherapy using a dominant tumor-specific T cell receptor. J Biol Chem (2013) 0.81
Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model. J Immunol (2016) 0.80
Enhanced antitumor effects of a dendritic cell vaccine transfected with gastric cancer cell total RNA carrying the 4-1BBL gene in vitro. Exp Ther Med (2011) 0.79
Elevated tumor-associated antigen expression suppresses variant peptide vaccine responses. J Immunol (2011) 0.78
Chitosan gel vaccine protects against tumour growth in an intracaecal mouse model of cancer by modulating systemic immune responses. BMC Immunol (2016) 0.76
Peptide Dose and/or Structure in Vaccines as a Determinant of T Cell Responses. Vaccines (Basel) (2014) 0.75
Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets. Hum Vaccin Immunother (2016) 0.75
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A (1993) 11.95
Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods (2003) 11.81
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998) 11.03
The three Es of cancer immunoediting. Annu Rev Immunol (2004) 8.20
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med (1998) 5.24
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol (2005) 3.73
Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med (2003) 3.60
Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med (1995) 2.80
Interface-disrupting amino acids establish specificity between T cell receptors and complexes of major histocompatibility complex and peptide. Nat Immunol (2006) 2.57
Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes. J Immunol (1993) 2.25
The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci U S A (1996) 2.24
A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother (2004) 2.16
An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity (1995) 2.14
Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity (2000) 2.13
Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J Exp Med (2000) 1.90
Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med (1997) 1.73
Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med (2009) 1.47
Relationships among TCR ligand potency, thresholds for effector function elicitation, and the quality of early signaling events in human T cells. J Immunol (1998) 1.44
Endogenous peptides of a soluble major histocompatibility complex class I molecule, H-2Lds: sequence motif, quantitative binding, and molecular modeling of the complex. J Exp Med (1992) 1.43
Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. J Clin Invest (2006) 1.40
Mimotopes for alloreactive and conventional T cells in a peptide-MHC display library. PLoS Biol (2004) 1.40
Diversity and recognition efficiency of T cell responses to cancer. PLoS Med (2004) 1.36
Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res (1997) 1.34
Use of baculovirus MHC/peptide display libraries to characterize T-cell receptor ligands. Immunol Rev (2006) 1.33
Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design. J Immunol (2005) 1.27
Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer (2003) 1.24
Direct detection of major histocompatibility complex class I binding to antigenic peptides using surface plasmon resonance. Peptide immobilization and characterization of binding specificity. J Biol Chem (1993) 1.13
Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1. J Immunother (2005) 1.10
Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma. J Gastroenterol (2009) 1.09
Class I major histocompatibility complex anchor substitutions alter the conformation of T cell receptor contacts. J Biol Chem (2001) 1.08
The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity. Eur J Immunol (2004) 1.08
Using a baculovirus display library to identify MHC class I mimotopes. Proc Natl Acad Sci U S A (2005) 1.07
Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer (1977) 1.06
Cutting edge: CD8+ T cell clones possess the potential to differentiate into both high- and low-avidity effector cells. J Immunol (2007) 1.06
Disulfide bond engineering to trap peptides in the MHC class I binding groove. J Immunol (2007) 1.02
The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope. J Immunol (2002) 1.00
Baculovirus-infected insect cells expressing peptide-MHC complexes elicit protective antitumor immunity. J Immunol (2008) 0.99
Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues. Int Immunol (1999) 0.98
Combinatorial peptide libraries as an alternative approach to the identification of ligands for tumor-reactive cytolytic T lymphocytes. Cancer Res (2001) 0.96
Distinct CD8+ T cell repertoires primed with agonist and native peptides derived from a tumor-associated antigen. J Immunol (2008) 0.96
Low-avidity self-specific T cells display a pronounced expansion defect that can be overcome by altered peptide ligands. J Immunol (2001) 0.93
Age-dependent tolerance to an endogenous tumor-associated antigen. Vaccine (2008) 0.92
Synthetic peptides as cancer vaccines. Biopolymers (2002) 0.86
Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule. Cancer Res (2001) 0.85
Phage display of peptide / major histocompatibility class I complexes. Eur J Immunol (2001) 0.81
How the T cell repertoire becomes peptide and MHC specific. Cell (2005) 3.39
The structure of a Bcl-xL/Bim fragment complex: implications for Bim function. Immunity (2003) 3.19
Chromogranin A is an autoantigen in type 1 diabetes. Nat Immunol (2010) 2.80
T cells down-modulate peptide-MHC complexes on APCs in vivo. Nat Immunol (2001) 2.80
Evolutionarily conserved amino acids that control TCR-MHC interaction. Annu Rev Immunol (2008) 2.79
Interface-disrupting amino acids establish specificity between T cell receptors and complexes of major histocompatibility complex and peptide. Nat Immunol (2006) 2.57
Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol (2009) 2.47
Germline-encoded amino acids in the alphabeta T-cell receptor control thymic selection. Nature (2009) 2.43
Crossreactive T Cells spotlight the germline rules for alphabeta T cell-receptor interactions with MHC molecules. Immunity (2008) 2.31
T cell allorecognition via molecular mimicry. Immunity (2009) 2.25
Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c⁺ B-cell population is important for the development of autoimmunity. Blood (2011) 2.20
Epitope dominance, competition and T cell affinity maturation. Curr Opin Immunol (2003) 2.09
Diabetogenic T cells recognize insulin bound to IAg7 in an unexpected, weakly binding register. Proc Natl Acad Sci U S A (2010) 1.87
A single T cell receptor bound to major histocompatibility complex class I and class II glycoproteins reveals switchable TCR conformers. Immunity (2011) 1.84
Specificity and detection of insulin-reactive CD4+ T cells in type 1 diabetes in the nonobese diabetic (NOD) mouse. Proc Natl Acad Sci U S A (2011) 1.68
High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. Hepatology (2013) 1.56
IgG autoantibodies against deposited C3 inhibit macrophage-mediated apoptotic cell engulfment in systemic autoimmunity. J Immunol (2011) 1.54
Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Res (2012) 1.53
Crystal structure of HLA-DP2 and implications for chronic beryllium disease. Proc Natl Acad Sci U S A (2010) 1.47
CD8 T cell competition for dendritic cells in vivo is an early event in activation. Proc Natl Acad Sci U S A (2006) 1.46
Memory CD4 T cells that express CXCR5 provide accelerated help to B cells. J Immunol (2011) 1.43
Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. J Clin Invest (2006) 1.40
Mimotopes for alloreactive and conventional T cells in a peptide-MHC display library. PLoS Biol (2004) 1.40
Interaction of JMJD6 with single-stranded RNA. Proc Natl Acad Sci U S A (2010) 1.37
Use of baculovirus MHC/peptide display libraries to characterize T-cell receptor ligands. Immunol Rev (2006) 1.33
CD4 memory T cells: what are they and what can they do? Semin Immunol (2009) 1.29
Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes. Cancer Res (2006) 1.25
Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. J Immunol (2003) 1.25
Genetic and hormonal factors in female-biased autoimmunity. Autoimmun Rev (2010) 1.24
Complex and dynamic redistribution of NF-kappaB signaling intermediates in response to T cell receptor stimulation. Proc Natl Acad Sci U S A (2004) 1.23
Host DNA released in response to aluminum adjuvant enhances MHC class II-mediated antigen presentation and prolongs CD4 T-cell interactions with dendritic cells. Proc Natl Acad Sci U S A (2013) 1.23
Immune mechanisms of protection: can adjuvants rise to the challenge? BMC Biol (2010) 1.22
Synergistic effect of a granulocyte-macrophage colony-stimulating factor-transduced tumor vaccine and systemic interleukin-2 in the treatment of murine colorectal cancer hepatic metastases. Ann Surg Oncol (2003) 1.18
Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells. Proc Natl Acad Sci U S A (2011) 1.18
Non-malignant clonal expansions of CD8+ memory T cells in aged individuals. Immunol Rev (2005) 1.17
Memory CD4 T cells: generation, reactivation and re-assignment. Immunology (2010) 1.16
Identification of two major types of age-associated CD8 clonal expansions with highly divergent properties. Proc Natl Acad Sci U S A (2008) 1.16
Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma. BMC Cancer (2010) 1.13
T cells and their eons-old obsession with MHC. Immunol Rev (2012) 1.13
Aluminum adjuvants elicit fibrin-dependent extracellular traps in vivo. Blood (2010) 1.12
Bim and Bcl-2 mutually affect the expression of the other in T cells. J Immunol (2007) 1.12
Not all CD4+ memory T cells are long lived. Immunol Rev (2006) 1.11
Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. Blood (2002) 1.10
Live attenuated Listeria monocytogenes effectively treats hepatic colorectal cancer metastases and is strongly enhanced by depletion of regulatory T cells. Cancer Res (2007) 1.08
T-box transcription factor T-bet, a key player in a unique type of B-cell activation essential for effective viral clearance. Proc Natl Acad Sci U S A (2013) 1.08
Mobilizing the low-avidity T cell repertoire to kill tumors. Semin Cancer Biol (2007) 1.08
The Epstein-Barr virus Bcl-2 homolog, BHRF1, blocks apoptosis by binding to a limited amount of Bim. Proc Natl Acad Sci U S A (2009) 1.08
Using a baculovirus display library to identify MHC class I mimotopes. Proc Natl Acad Sci U S A (2005) 1.07
A modified tyrosinase-related protein 2 epitope generates high-affinity tumor-specific T cells but does not mediate therapeutic efficacy in an intradermal tumor model. J Immunol (2006) 1.06
Evolutionarily conserved features contribute to αβ T cell receptor specificity. Immunity (2011) 1.06
Many different Vbeta CDR3s can reveal the inherent MHC reactivity of germline-encoded TCR V regions. Proc Natl Acad Sci U S A (2009) 1.04
Yeast surface display of a noncovalent MHC class II heterodimer complexed with antigenic peptide. Biotechnol Bioeng (2005) 1.01
Baculovirus-infected insect cells expressing peptide-MHC complexes elicit protective antitumor immunity. J Immunol (2008) 0.99
Macrophages mediate lung inflammation in a mouse model of ischemic acute kidney injury. Am J Physiol Renal Physiol (2011) 0.98
CD8 T cell clonal expansions & aging: a heterogeneous phenomenon with a common outcome. Exp Gerontol (2007) 0.98
Identification of beryllium-dependent peptides recognized by CD4+ T cells in chronic beryllium disease. J Exp Med (2013) 0.95
Stronger correlation of bcl-3 than bcl-2, bcl-xL, costimulation, or antioxidants with adjuvant-induced T cell survival. Ann N Y Acad Sci (2002) 0.95
Gr1+IL-4-producing innate cells are induced in response to Th2 stimuli and suppress Th1-dependent antibody responses. Int Immunol (2008) 0.94
A conserved CXXC motif in CD3epsilon is critical for T cell development and TCR signaling. PLoS Biol (2009) 0.94
Specificity of regulatory CD4+CD25+ T cells for self-T cell receptor determinants. J Neurosci Res (2004) 0.94
Immunization with an insulin peptide-MHC complex to prevent type 1 diabetes of NOD mice. Diabetes Metab Res Rev (2011) 0.93
Do MHCII-presented neoantigens drive type 1 diabetes and other autoimmune diseases? Cold Spring Harb Perspect Med (2012) 0.92
TLR7 drives accumulation of ABCs and autoantibody production in autoimmune-prone mice. Immunol Res (2013) 0.92
Galectin-9 functionally impairs natural killer cells in humans and mice. J Virol (2013) 0.92
Mutagenesis of beryllium-specific TCRs suggests an unusual binding topology for antigen recognition. J Immunol (2011) 0.92
T cell receptor specificity for major histocompatibility complex proteins. Curr Opin Immunol (2008) 0.92
Homeostasis of the memory T cell pool. Int Arch Allergy Immunol (2006) 0.91
A closer look at TCR germline recognition. Immunity (2012) 0.91
The structure of HLA-DR52c: comparison to other HLA-DRB3 alleles. Proc Natl Acad Sci U S A (2008) 0.91
Improving T cell responses to modified peptides in tumor vaccines. Immunol Res (2013) 0.90
TCR hypervariable regions expressed by T cells that respond to effective tumor vaccines. Cancer Immunol Immunother (2012) 0.89
Effective functional maturation of invariant natural killer T cells is constrained by negative selection and T-cell antigen receptor affinity. Proc Natl Acad Sci U S A (2013) 0.88
T-cell receptor (TCR) interaction with peptides that mimic nickel offers insight into nickel contact allergy. Proc Natl Acad Sci U S A (2012) 0.87
Monoclonal antibody blocking the recognition of an insulin peptide-MHC complex modulates type 1 diabetes. Proc Natl Acad Sci U S A (2014) 0.86
Bcl-xl does not have to bind Bax to protect T cells from death. J Exp Med (2006) 0.85
Influenza nucleoprotein delivered with aluminium salts protects mice from an influenza A virus that expresses an altered nucleoprotein sequence. PLoS One (2013) 0.84
Identification of multiple public TCR repertoires in chronic beryllium disease. J Immunol (2014) 0.84
Augmenting antitumor T-cell responses to mimotope vaccination by boosting with native tumor antigens. Cancer Res (2012) 0.84
B cells expressing the transcription factor T-bet drive lupus-like autoimmunity. J Clin Invest (2017) 0.83
Linking genetic susceptibility and T cell activation in beryllium-induced disease. Proc Am Thorac Soc (2010) 0.81
Improving antigenic peptide vaccines for cancer immunotherapy using a dominant tumor-specific T cell receptor. J Biol Chem (2013) 0.81
Influence of human immune cells on cancer: studies at the University of Colorado. Immunol Res (2013) 0.80
Thymic selection stifles TCR reactivity with the main chain structure of MHC and forces interactions with the peptide side chains. Mol Immunol (2008) 0.80
Normal development of mice deficient in beta 2M, MHC class I proteins, and CD8+ T cells. 1990. J Immunol (2010) 0.79
Transgenic Bcl-3 slows T cell proliferation. Int Immunol (2009) 0.79
Ikaros promotes rearrangement of TCR α genes in an Ikaros null thymoma cell line. Eur J Immunol (2012) 0.78
Molecules in medicine mini review: the αβ T cell receptor. J Mol Med (Berl) (2014) 0.78
Elevated tumor-associated antigen expression suppresses variant peptide vaccine responses. J Immunol (2011) 0.78
Vaccination of mice with baculovirus-infected insect cells expressing antigenic proteins. Curr Protoc Immunol (2009) 0.77
The Ikaros transcription factor regulates responsiveness to IL-12 and expression of IL-2 receptor alpha in mature, activated CD8 T cells. PLoS One (2013) 0.76
Mimotope vaccine efficacy gets a "boost" from native tumor antigens. Oncoimmunology (2013) 0.75
Correction: Free Fatty Acids Differentially Downregulate Chemokines in Liver Sinusoidal Endothelial Cells: Insights into Non-Alcoholic Fatty Liver Disease. PLoS One (2016) 0.75
Pillars Article: Characterization of a Monoclonal Antibody Which Detects All Murine αβ T Cell Receptors. J. Immunol. 1989. 142: 2736-2742. J Immunol (2016) 0.75